Top of this page
Skip navigation, go straight to the content

UCB's new development pipeline

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



Neurology Indications Phase 1 Phase 2 Phase 3 Filed
Vimpat®epilepsy – various indications – life cycle management
 
UCB0942 (PPSI)epilepsy – highly drug resistant
phase 2 half
UCB1332 / NTP200-11*Parkinson's disease
phase 1 half
UCB3491Epilepsy
phase 1 quarter
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
Cimzia®immunological diseases – various indications – life cycle management 
romosozumab**post-menopausal osteoporosis +
osteoporosis in men
phase 3
bimekizumab (IL17AF)various arthritis and dermatology indicationsphase 2 three quarter
bimekizumab &
Cimzia® combo
rheumatoid arthritisphase 2 half
seletalisib
(PI3K Delta inhibitor)
Sjörgen's syndrome + APDSphase 2 half
dapirolizumab pegol (CD40L antibody)***systemic lupus erythematosusphase 2 half
UCB7665immunological diseasesphase 2 half
UCB4144 / VR942*****asthmaphase 2
UCB6673**** immunological diseasesphase 1 half
1.Paediatric 2-17 years
2.Primary generalised tonic clonic seizures
*
**
***
****
*****
In collaboration with Neuropore
In collaboration with Amgen
In collaboration with Biogen
In collaboration with King's College
In collaboration with Vectura